glp 1 pdb RCSB Diversified ECD engagements in GLP-1R
Description
Genetics Medicine of African Populations (GeneMAP) Research Group, Faculty of Health Sciences, University of Cape Town
Major Market Trends Rapid adoption of GLP-1 receptor agonists as first-line obesity treatments due to strong real-world weight-loss outcomes
However, these drugs can cause gastrointestinal side effects, such as nausea and diarrhoea
No, Trulicity is FDA-approved only for Type 2 diabetes, not weight loss
